OBJECTIVE: Myeloperoxidase (MPO) is a leukocyte-derived enzyme that appears to be directly involved in atherosclerosis development. We evaluated the association of circulating MPO with coronary and aortic atherosclerosis in a large, multiethnic population. METHODS AND RESULTS: Plasma levels of MPO were measured in 3294 subjects participating in the Dallas Heart Study, a probability-based population sample. Coronary artery calcification (CAC) was measured by EBCT, and abdominal aorta plaque prevalence (AP) and burden (APB), as well as abdominal aorta wall thickness (AWT) were determined by MRI. Associations between MPO and atherosclerosis phenotypes were assessed in multivariable analyses adjusting for traditional atherosclerosis risk factors. MPO levels in the 4th compared with 1st quartile independently associated with prevalent AP (OR 1.41, 95% CI 1.08-1.84), APB (beta coefficient 0.23, p = 0.02), and AWT (beta coefficient 0.04, p = 0.03), but not with prevalent CAC (OR 0.84, 95% CI 0.61-1.17). MPO remained associated with aortic atherosclerosis phenotypes but not coronary calcification after adjustment for other inflammatory biomarkers. A significant interaction was observed between race/ethnicity, MPO and AP (p(interaction) = 0.038), such that MPO levels in the 4th vs 1st quartile associated with prevalent AP in African Americans, (OR 1.81, 95% CI 1.23-2.65) but not in White or Hispanic participants (OR 0.99, 95% CI 0.68-1.44). CONCLUSION: Higher levels of MPO associated with aortic but not coronary atherosclerosis, with significant associations limited to African American participants. These findings suggest that MPO might be a novel risk factor contributing to racial disparities in peripheral vascular disease.
OBJECTIVE:Myeloperoxidase (MPO) is a leukocyte-derived enzyme that appears to be directly involved in atherosclerosis development. We evaluated the association of circulating MPO with coronary and aortic atherosclerosis in a large, multiethnic population. METHODS AND RESULTS: Plasma levels of MPO were measured in 3294 subjects participating in the Dallas Heart Study, a probability-based population sample. Coronary artery calcification (CAC) was measured by EBCT, and abdominal aorta plaque prevalence (AP) and burden (APB), as well as abdominal aorta wall thickness (AWT) were determined by MRI. Associations between MPO and atherosclerosis phenotypes were assessed in multivariable analyses adjusting for traditional atherosclerosis risk factors. MPO levels in the 4th compared with 1st quartile independently associated with prevalent AP (OR 1.41, 95% CI 1.08-1.84), APB (beta coefficient 0.23, p = 0.02), and AWT (beta coefficient 0.04, p = 0.03), but not with prevalent CAC (OR 0.84, 95% CI 0.61-1.17). MPO remained associated with aortic atherosclerosis phenotypes but not coronary calcification after adjustment for other inflammatory biomarkers. A significant interaction was observed between race/ethnicity, MPO and AP (p(interaction) = 0.038), such that MPO levels in the 4th vs 1st quartile associated with prevalent AP in African Americans, (OR 1.81, 95% CI 1.23-2.65) but not in White or Hispanic participants (OR 0.99, 95% CI 0.68-1.44). CONCLUSION: Higher levels of MPO associated with aortic but not coronary atherosclerosis, with significant associations limited to African American participants. These findings suggest that MPO might be a novel risk factor contributing to racial disparities in peripheral vascular disease.
Authors: Ann B Nguyen; Anand Rohatgi; Christine K Garcia; Colby R Ayers; Sandeep R Das; Susan G Lakoski; Jarett D Berry; Amit Khera; Darren K McGuire; James A de Lemos Journal: Arterioscler Thromb Vasc Biol Date: 2011-08-04 Impact factor: 8.311
Authors: Farouc A Jaffer; Christopher J O'Donnell; Martin G Larson; Stephen K Chan; Kraig V Kissinger; Michelle J Kupka; Carol Salton; Rene M Botnar; Daniel Levy; Warren J Manning Journal: Arterioscler Thromb Vasc Biol Date: 2002-05-01 Impact factor: 8.311
Authors: R Zhang; M L Brennan; X Fu; R J Aviles; G L Pearce; M S Penn; E J Topol; D L Sprecher; S L Hazen Journal: JAMA Date: 2001-11-07 Impact factor: 56.272
Authors: Nathan D Wong; Heidi Gransar; Jagat Narula; Leslee Shaw; Johanna H Moon; Romalisa Miranda-Peats; Alan Rozanski; Sean W Hayes; Louise E J Thomson; John D Friedman; Daniel S Berman Journal: JACC Cardiovasc Imaging Date: 2009-09
Authors: Marie-Luise Brennan; Marc S Penn; Frederick Van Lente; Vijay Nambi; Mehdi H Shishehbor; Ronnier J Aviles; Marlene Goormastic; Michael L Pepoy; Ellen S McErlean; Eric J Topol; Steven E Nissen; Stanley L Hazen Journal: N Engl J Med Date: 2003-10-23 Impact factor: 91.245
Authors: Renliang Zhang; Marie-Luise Brennan; Zhongzhou Shen; Jennifer C MacPherson; Dave Schmitt; Cheryl E Molenda; Stanley L Hazen Journal: J Biol Chem Date: 2002-09-30 Impact factor: 5.157
Authors: Iftikhar J Kullo; Kent R Bailey; Sharon L R Kardia; Thomas H Mosley; Eric Boerwinkle; Stephen T Turner Journal: Vasc Med Date: 2003-11 Impact factor: 3.239
Authors: Stephan Baldus; Christopher Heeschen; Thomas Meinertz; Andreas M Zeiher; Jason P Eiserich; Thomas Münzel; Maarten L Simoons; Christian W Hamm Journal: Circulation Date: 2003-09-02 Impact factor: 29.690
Authors: Htet W Khine; John F Teiber; Robert W Haley; Amit Khera; Colby R Ayers; Anand Rohatgi Journal: Atherosclerosis Date: 2017-06-03 Impact factor: 5.162
Authors: Christina Charles-Schoeman; Yuen Yin Lee; Ani Shahbazian; Xiaoyan Wang; David Elashoff; Jeffrey R Curtis; Iris Navarro-Millán; Shuo Yang; Lang Chen; Stacey S Cofield; Larry W Moreland; Harold Paulus; James O'Dell; Joan Bathon; S Louis Bridges; Srinivasa T Reddy Journal: Arthritis Rheumatol Date: 2017-01 Impact factor: 15.483
Authors: C M Gijsberts; A Seneviratna; I E M Bank; H M den Ruijter; F W Asselbergs; P Agostoni; J A Remijn; G Pasterkamp; H C Kiat; M Roest; A M Richards; M Y Chan; D P V de Kleijn; I E Hoefer Journal: Neth Heart J Date: 2016-03 Impact factor: 2.380